139 related articles for article (PubMed ID: 37689733)
1. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.
Qi C; Xie T; Zhou J; Wang X; Gong J; Zhang X; Li J; Yuan J; Liu C; Shen L
J Hematol Oncol; 2023 Sep; 16(1):102. PubMed ID: 37689733
[TBL] [Abstract][Full Text] [Related]
2. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
Qi C; Gong J; Li J; Liu D; Qin Y; Ge S; Zhang M; Peng Z; Zhou J; Cao Y; Zhang X; Lu Z; Lu M; Yuan J; Wang Z; Wang Y; Peng X; Gao H; Liu Z; Wang H; Yuan D; Xiao J; Ma H; Wang W; Li Z; Shen L
Nat Med; 2022 Jun; 28(6):1189-1198. PubMed ID: 35534566
[TBL] [Abstract][Full Text] [Related]
3. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report.
Zhong G; Zhang X; Guo Z; Gao Y; Zhao B; Liu X; Chen L; Qiao J; Yu C; Wang L; Li Y; Yu L
Front Immunol; 2024; 15():1325860. PubMed ID: 38487523
[TBL] [Abstract][Full Text] [Related]
4. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
5. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
6. A major role for CD4
Boulch M; Cazaux M; Cuffel A; Ruggiu M; Allain V; Corre B; Loe-Mie Y; Hosten B; Cisternino S; Auvity S; Thieblemont C; Caillat-Zucman S; Bousso P
Cell Rep Med; 2023 Sep; 4(9):101161. PubMed ID: 37595589
[TBL] [Abstract][Full Text] [Related]
7. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
9. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
[TBL] [Abstract][Full Text] [Related]
10. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
[TBL] [Abstract][Full Text] [Related]
11. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses.
Bove C; Arcangeli S; Falcone L; Camisa B; El Khoury R; Greco B; De Lucia A; Bergamini A; Bondanza A; Ciceri F; Bonini C; Casucci M
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593069
[TBL] [Abstract][Full Text] [Related]
12. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
[TBL] [Abstract][Full Text] [Related]
13. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
14. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
Tanyi JL; Stashwick C; Plesa G; Morgan MA; Porter D; Maus MV; June CH
J Immunother; 2017 Apr; 40(3):104-107. PubMed ID: 28234665
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
19. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
20. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
[Next] [New Search]
